4-phenylmethylamino-7-fluoro-2-(pyridin-3-yl)quinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-phenylmethylamino-7-fluoro-2-(pyridin-3-yl)quinazoline
• 英文别名: 4-Phenylmethylamino-7-Fluoro-2-(3-Pyridyl)Quinazoline；Benzyl-(7-fluoro-2-pyridin-3-yl-quinazolin-4-yl)-amine; dihydrochloride；N-benzyl-7-fluoro-2-pyridin-3-ylquinazolin-4-amine
• 化学式: C₂₀H₁₅FN₄
• 分子量: 330.364
• InChiKey: ACYITABPULQXIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氯化烟碱盐酸盐 在 sodium methylate 、 N,N-二甲基苯胺 、 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 59.5h， 生成 4-phenylmethylamino-7-fluoro-2-(pyridin-3-yl)quinazoline
  参考文献：
  名称：

  Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities

  摘要：

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.

  DOI：

  10.1021/jm00018a014

文献信息

• Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
  申请人：——

  公开号：US20020025968A1

  公开（公告）日：2002-02-28

  A method for inhibiting neoplastic cells and related conditions by exposing them to 4-aminoquinazoline derivatives.

  通过将肿瘤细胞暴露于4-氨基喹噁啉衍生物来抑制肿瘤细胞和相关疾病的方法。
• 4-Aminoquinazoline derivatives, and their use as medicine
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0579496B1

  公开（公告）日：2001-11-14
• US5436233A
  申请人：——

  公开号：US5436233A

  公开（公告）日：1995-07-25
• US5439895A
  申请人：——

  公开号：US5439895A

  公开（公告）日：1995-08-08
• Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities
  作者：Sung J. Lee、Yoshitaka Konishi、Dingwei T. Yu、Tamara A. Miskowski、Christopher M. Riviello、Orest T. Macina、Manton R. Frierson、Kigen Kondo、Masafumi Sugitani

  DOI：10.1021/jm00018a014

  日期：1995.9

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.